During September 5th -8th, the Society for the Study of Dermatovenereologic and Allergic Diseases (S.S.D.A.D.) held the 2nd Panhellenic Conference at Zappeion Aegli, Athens, under the theme: “Dermatological diseases 2019: Past, present and future”. IASIS PHARMA was present, participating dynamically once more in the field of Dermatology.
Dermatologists who attended the Conference had the chance to visit IASIS PHARMA exhibition stand and received information about three of its major Dermatological products.
Ιsotroin®, isotretinoin, a retinoid for the treatment of acne, available in 3 strengths: soft caps of 10mg, 20mg and the unique 40mg strength, helping the dermatologist to better customize the patient’s dosage scheme.
Special interest was shown for Modiwart®, with imiquimod as its active ingredient. Modiwart® is an innovative immunomodulator, with the following indications: external genital warts and anogenital (acuminate warts) in adults, small superficial basal cell carcinomas (sBCC) and clinically typical actinic keratoses (AKs). Modiwart® is distributed in the form of a cream for topical use in 12 sachets package. Each sachet contains 12,5 mg imiquimod in 250 mg cream (5%).
Combi® was also displayed, which is a combination of miconazole + fluprednidene in the form of cream with excellent texture and the advantage of the 50g pack.